On August 21, according to the 2024 semi-annual report of SciTop Biotech, the company achieved a revenue of approximately USD 18.9 million in the first half of the year, a decrease of 1.34% year-on-year. The net profit reached approximately USD 5.95 million, an increase of 7.89% year-on-year.
From a business segment perspective, in the first half of the year, the revenue from SciTop Biotech’s edible probiotics products, animal and plant microecological preparations, compound food additives, and probiotics technology services were approximately USD 13.9 million, USD 2.06 million, USD 2.49 million, and USD 0.28 million, respectively. The year-on-year changes for these segments were 18.15%, 86.02%, -56.35%, and -33.23%, respectively.
SciTop Biotech stated that the growth in revenue from the edible probiotics segment in the first half of the year provided a strong guarantee for the company’s overall performance. The compound food additives business experienced a decline compared to the same period last year due to the continuous downward trend in the product lifecycle of downstream products. However, since it accounts for less than 14% of total revenue, the impact on overall performance is minimal. Currently, the edible probiotics business has become the main support and key growth driver for the company’s revenue. Source: Beijing News
Sign Up to Receive China Updates Weekly Newsletter for FREE, HERE
Visit HPA-China’s Information Hub, HERE